ImmunityBio, Inc. Common Stock insider trading
IBRXfinancial statementsForm 4 filings on EDGAR70 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at ImmunityBio, Inc. Common Stock bought $0 of stock in the open market, and 2 sold $1M. Officers and directors accounted for $0 of purchases and $1M of sales. The last reported transaction was an open-market sale by Simon Barry J. on October 5, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 6, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $1MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
70 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 25,000 | $10.75 | $269K | 3M | Oct 6, 2026 |
| Oct 2, 2026 | Cohen Cheryl | Director | option exercise | 55,979 | $2.98 | $167K | 181,365 | Oct 6, 2026 |
| Oct 2, 2026 | Cohen Cheryl | Director | open-market sale10b5-1 | 81,056 | $10.50 | $851K | 100,309 | Oct 6, 2026 |
| Jul 2, 2026 | Cohen Cheryl | Director | option exercise | 55,979 | $2.98 | $167K | 256,596 | Jul 6, 2026 |
| Jul 2, 2026 | Cohen Cheryl | Director | open-market sale10b5-1 | 131,210 | $9.50 | $1M | 125,386 | Jul 6, 2026 |
| Jul 1, 2026 | Selecky Christobel | Director | option exercise | 35,064 | $2.98 | $104K | 35,064 | Jul 6, 2026 |
| Jul 1, 2026 | Selecky Christobel | Director | option exercise | 124,414 | $2.99 | $372K | 159,478 | Jul 6, 2026 |
| Jul 1, 2026 | Selecky Christobel | Director | open-market sale10b5-1 | 159,478 | $9.02 | $1M | 0 | Jul 6, 2026 |
| Jun 30, 2026 | Selecky Christobel | Director | option exercise | 700 | $2.98 | $2K | 700 | Jul 1, 2026 |
| Jun 30, 2026 | Selecky Christobel | Director | option exercise | 300 | $2.99 | $897 | 1,000 | Jul 1, 2026 |
| Jun 30, 2026 | Selecky Christobel | Director | open-market sale10b5-1 | 1,000 | $9.00 | $9K | 0 | Jul 1, 2026 |
| Jun 29, 2026 | Selecky Christobel | Director | option exercise | 32,173 | $2.98 | $96K | 32,173 | Jul 1, 2026 |
| Jun 29, 2026 | Selecky Christobel | Director | option exercise | 33,549 | $2.99 | $100K | 65,722 | Jul 1, 2026 |
| Jun 29, 2026 | Selecky Christobel | Director | option exercise | 30,000 | $2.84 | $85K | 95,722 | Jul 1, 2026 |
| Jun 29, 2026 | Selecky Christobel | Director | open-market sale10b5-1 | 95,722 | $9.01 | $862K | 0 | Jul 1, 2026 |
| Jun 24, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 25,000 | $7.88 | $197K | 3M | Jun 26, 2026 |
| Jun 4, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 23,033 | $7.18 | $165K | 3M | Jun 5, 2026 |
| Mar 31, 2026 | Soon-Shiong Patrick+4 more | See remarks, Director, 10% owner | conversionindirect | 5M | $5.43 | $25M | 251M | Apr 2, 2026 |
| Feb 24, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 75,000 | $12.01 | $901K | 3M | Feb 26, 2026 |
| Feb 23, 2026 | Selecky Christobel | Director | option exercise | 25,000 | $2.98 | $75K | 25,000 | Feb 24, 2026 |
| Feb 23, 2026 | Selecky Christobel | Director | open-market sale10b5-1 | 25,000 | $10.00 | $250K | 0 | Feb 24, 2026 |
| Feb 23, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 165,000 | $10.25 | $2M | 3M | Feb 24, 2026 |
| Feb 22, 2026 | Sachs David C. | Chief Financial Officer | tax withholding | 20,682 | $8.70 | $180K | 300,143 | Feb 24, 2026 |
| Feb 22, 2026 | Sachs David C. | Chief Financial Officer | option exercise | 40,650 | $0.00 | — | 320,825 | Feb 24, 2026 |
| Feb 22, 2026 | California Capital Equity, LLC+4 more | 10% owner | tax withholding | 58,170 | $8.70 | $506K | 30M | Feb 24, 2026 |
| Feb 22, 2026 | California Capital Equity, LLC+4 more | 10% owner | option exercise | 114,329 | $0.00 | — | 30M | Feb 24, 2026 |
| Feb 22, 2026 | Lauer Regan J | Chief Accounting Officer | option exercise | 4,065 | $0.00 | — | 117,548 | Feb 24, 2026 |
| Feb 22, 2026 | Lauer Regan J | Chief Accounting Officer | tax withholding | 1,673 | $8.70 | $15K | 115,875 | Feb 24, 2026 |
| Feb 22, 2026 | Adcock Richard | CEO & President, Director | option exercise | 152,439 | $0.00 | — | 637,904 | Feb 24, 2026 |
| Feb 22, 2026 | Adcock Richard | CEO & President, Director | tax withholding | 77,560 | $8.70 | $675K | 560,344 | Feb 24, 2026 |
| Feb 22, 2026 | Simon Barry J. | Director | tax withholding | 6,026 | $8.70 | $52K | 3M | Feb 24, 2026 |
| Feb 22, 2026 | Simon Barry J. | Director | option exercise | 15,243 | $0.00 | — | 3M | Feb 24, 2026 |
| Feb 20, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 10,000 | $9.25 | $93K | 3M | Feb 24, 2026 |
| Feb 10, 2026 | Soon-Shiong Patrick+4 more | See remarks, Director, 10% owner | option exercise | 274,122 | $0.00 | — | 30M | Feb 12, 2026 |
| Feb 10, 2026 | Soon-Shiong Patrick+4 more | See remarks, Director, 10% owner | tax withholding | 118,560 | $6.93 | $822K | 30M | Feb 12, 2026 |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | option exercise | 82,236 | $0.00 | — | 322,818 | Feb 12, 2026 |
| Feb 10, 2026 | Sachs David C. | Chief Financial Officer | tax withholding | 42,643 | $6.93 | $296K | 280,175 | Feb 12, 2026 |
| Feb 10, 2026 | Lauer Regan J | Chief Accounting Officer | tax withholding | 2,257 | $6.93 | $16K | 113,483 | Feb 12, 2026 |
| Feb 10, 2026 | Lauer Regan J | Chief Accounting Officer | option exercise | 5,482 | $0.00 | — | 115,740 | Feb 12, 2026 |
| Feb 10, 2026 | Adcock Richard | CEO & President, Director | option exercise | 274,122 | $0.00 | — | 625,513 | Feb 12, 2026 |
| Feb 10, 2026 | Adcock Richard | CEO & President, Director | tax withholding | 140,048 | $6.93 | $971K | 485,465 | Feb 12, 2026 |
| Jan 20, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 75,000 | $7.88 | $591K | 3M | Jan 21, 2026 |
| Jan 20, 2026 | Simon Barry J. | Director | open-market sale10b5-1 | 76,967 | $6.54 | $503K | 3M | Jan 21, 2026 |
| Jan 20, 2026 | Selecky Christobel | Director | option exercise | 25,000 | $2.98 | $75K | 25,000 | Jan 21, 2026 |
| Jan 20, 2026 | Selecky Christobel | Director | open-market sale10b5-1 | 25,000 | $7.51 | $188K | 0 | Jan 21, 2026 |
| Jan 16, 2026 | Selecky Christobel | Director | option exercise | 50,000 | $2.98 | $149K | 50,000 | Jan 21, 2026 |
| Jan 16, 2026 | Selecky Christobel | Director | open-market sale10b5-1 | 50,000 | $5.00 | $250K | 0 | Jan 21, 2026 |
| Dec 31, 2025 | Sachs David C. | Chief Financial Officer | tax withholding | 15,435 | $1.98 | $31K | 240,582 | Jan 5, 2026 |
| Dec 31, 2025 | Sachs David C. | Chief Financial Officer | option exercise | 30,397 | $0.00 | — | 256,017 | Jan 5, 2026 |
| Dec 31, 2025 | Adcock Richard | CEO & President, Director | tax withholding | 17,510 | $1.98 | $35K | 351,391 | Jan 5, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Simon Barry J. | Director | Oct 5, 2026 | open-market sale | 3M | — | $4M (8) | 8 of 8 |
| Selecky Christobel | Director | Jul 1, 2026 | option exercise | 35,064 | — | $3M (6) | 6 of 6 |
| Cohen Cheryl | Director | Oct 2, 2026 | option exercise | 181,365 | — | $2M (2) | 2 of 2 |
| Sachs David C. | Chief Financial Officer | Feb 22, 2026 | tax withholding | 300,143 | — | — | — |
| Adcock Richard | CEO & President, Director | Feb 22, 2026 | option exercise | 637,904 | — | — | — |
| Lauer Regan J | Chief Accounting Officer | Feb 22, 2026 | option exercise | 117,548 | — | — | — |
| Soon-Shiong Patrick | See remarks, Director, 10% owner | Mar 31, 2026 | conversion | 30M | — | — | — |
| California Capital Equity, LLC | 10% owner | Feb 22, 2026 | tax withholding | 30M | — | — | — |
Questions
Are ImmunityBio, Inc. Common Stock insiders buying or selling?
Over the twelve months to November 3, 2026, 3 insiders at ImmunityBio, Inc. Common Stock sold $10M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $10M. Only open-market purchases and sales are counted.
Who sold the most ImmunityBio, Inc. Common Stock stock in the last year?
Simon Barry J. (Director) sold $4M in 8 open-market sales over the twelve months to November 3, 2026.
Do ImmunityBio, Inc. Common Stock executives sell under 10b5-1 plans?
16 of the 16 open-market sales in the last twelve months (100%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on ImmunityBio, Inc. Common Stock
- ImmunityBio, Inc. Common Stock financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.